Core Viewpoint - Liquidia Corporation (LQDA) has shown a significant price increase of 30.1% over the past four weeks, with a mean price target of $44 indicating a potential upside of 51.2% from the current price of $29.11 [1] Price Targets and Analyst Consensus - The average price target for LQDA includes nine estimates ranging from a low of $16.00 to a high of $67.00, with a standard deviation of $14.33, indicating variability in analyst predictions [2] - The lowest estimate suggests a potential decline of 45%, while the highest indicates a possible upside of 130.2% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about LQDA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 50.8%, with five estimates moving higher and no negative revisions [12] - LQDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

TTM Technologies (TTMI) closed the last trading session at $58.45, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $76 indicates a 30% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $3.16. While the lowest estimate of $72.00 indicates a 23.2% increase from the current price level, the most optimistic analyst expe ...

Core Viewpoint - Tango Therapeutics, Inc. (TNGX) has seen an 18.2% increase in share price over the past four weeks, closing at $8.9, with a potential upside of 46.1% based on Wall Street analysts' mean price target of $13 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $1.31, indicating variability among analysts [2]. - The lowest price target is $11.00, suggesting a 23.6% increase, while the highest target is $15.00, indicating a potential surge of 68.5% [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about TNGX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 15.1%, with six estimates moving higher and no negative revisions [12]. - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the stock's potential gain, the implied direction of price movement appears to be a useful guide [14].

Core Viewpoint - Enanta Pharmaceuticals (ENTA) shares have increased by 13.7% in the past four weeks, closing at $12.13, with a potential upside of 44.9% based on Wall Street analysts' mean price target of $17.57 [1][4]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates, with a standard deviation of $5.44, indicating variability among analysts [2]. - The lowest estimate is $9.00, suggesting a 25.8% decline from the current price, while the highest estimate is $25.00, indicating a potential surge of 106.1% [2]. - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ENTA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which have increased by 22.4% over the past month [11][12]. - The Zacks Consensus Estimate for the current year reflects this optimism, with no negative revisions reported [12]. - ENTA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While consensus price targets are a common metric for investors, relying solely on them for investment decisions may not be prudent due to historical inaccuracies [3][10]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8].

Alarm.com Holdings (ALRM) closed the last trading session at $50.3, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.71 indicates a 32.6% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $12.19. While the lowest estimate of $55.00 indicates a 9.3% increase from the current price level, the most optimistic analy ...

Shares of McGraw Hill, Inc. (MH) have gained 25.8% over the past four weeks to close the last trading session at $15.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $20.83 indicates a potential upside of 32.4%.The average comprises 12 short-term price targets ranging from a low of $16.00 to a high of $27.00, with a standard deviation of $3.07. While the lowest estimate indic ...

Core Viewpoint - James River Group (JRVR) shares have increased by 6.5% recently, with a mean price target of $7.06 indicating a potential upside of 26.8% from the current price of $5.57 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $1.09, where the lowest estimate is $6.00 (7.7% increase) and the highest is $8.00 (43.6% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about JRVR's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which have increased by 10.5% over the past month [11][12] - The Zacks Consensus Estimate indicates that JRVR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as empirical research shows that they often mislead investors [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - nLight (LASR) shows potential for significant upside, with a mean price target of $39.83 indicating a 30.6% increase from the current price of $30.5 [1] Price Targets and Analyst Consensus - The average price target consists of six estimates ranging from $30.00 to $50.00, with a standard deviation of $6.34, indicating variability among analysts [2] - The lowest estimate suggests a decline of 1.6%, while the highest points to a 63.9% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about LASR's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 7.5% over the past month, with no negative revisions [12] - LASR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has shown a significant price increase of 22.2% over the past four weeks, with a mean price target of $23 indicating a potential upside of 161.4% from its current price of $8.8 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $16.00 to a high of $29.00, with a standard deviation of $4.93, indicating variability among analysts [2] - The lowest estimate suggests an increase of 81.8%, while the highest points to a 229.6% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding the price movement direction [9] Analyst Sentiment - Analysts are optimistic about DAWN's earnings prospects, as evidenced by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [11] - Over the last 30 days, six earnings estimates have been revised higher, resulting in an 18.2% increase in the Zacks Consensus Estimate [12] Zacks Rank - DAWN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful indication of the expected direction of price movement [14]

Core Viewpoint - Trimble Navigation (TRMB) shows potential for significant upside, with a mean price target of $98.11 indicating a 26.5% increase from its current price of $77.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $2.76, suggesting a consensus among analysts [2] - The lowest price target is $93.00, indicating a 19.9% increase, while the highest target is $102.00, suggesting a 31.5% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about TRMB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 5.2% over the past month, with six estimates revised upward and no negative revisions [12] - TRMB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][10] - Price targets can be influenced by business incentives, leading to overly optimistic estimates [8]